WALTER YUKIHIKO TAKAHASHI
Projetos de Pesquisa
Unidades Organizacionais
LIM/33 - Laboratório de Oftalmologia, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Enhanced Depth Image Optical Coherence Tomography (EDI-OCT) choroidal evaluation in patients with diabetes and correlation with retinal and kidney disease(2016) ABALEM, Maria Fernanda; PRETI, Rony Carlos; GARCIA, Rafael; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro C.; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.- Idiopathic Organ Transplant Chorioretinopathy after Liver Transplantation(2015) ABALEM, Maria Fernanda; CARRICONDO, Pedro Carlos; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter YukihikoIdiopathic organ transplant chorioretinopathy is a rare disease associated with kidney and heart transplantation. We present a case secondary to liver transplantation including its multimodal imaging, differential diagnosis, and physiopathology discussion.
conferenceObject Correlation of Enhanced Depht Imaging Optical Coherence Tomography (EDI-OCT) choroidal findings and visual acuity in sickle cell disease(2016) CARRICONDO, Pedro C.; ABALEM, Maria Fernanda; BONANOMI, Maria Teresa B. C.; PRETI, Rony; PIMENTEL, Sergio Luis Gianotti; MONTEIRO, Mario L. R.; TAKAHASHI, Walter Y.- Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration(2015) MEDINA, Flavio Mac Cord; MOTTA, Augusto Alves Lopes da; TAKAHASHI, Walter Y.; CARRICONDO, Pedro Carlos; MOTTA, Mario Martins dos Santos; MELO, Monica B.; VASCONCELLOS, Jose Paulo C.Purpose: To compare the functional and morphological response to the initial intravitreal (IV) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population. Methods: Twenty-five unrelated patients with treatment-naive exudative AMD underwent an IVT injection of 1.25 mg bevacizumab at the initial presentation (DO) and were reexamined 7 days (D7) and 28 days (D28) later. The time and extent of visual acuity (VA) and central retinal thickness (CRT) changes were evaluated according to the presence of the T1277C polymorphism. Results: In the homozygous risk group (CC), VA improvement was detected mostly from D7 to D28, while in the heterozygous (CT) and homozygous for the wild-type allele (TT) groups, functional response occurred earlier, from DO to D7. Morphological response to the first IVT injection of bevacizunnab was significant in the CT and TT groups, while the CC group presented no significant change in CRT up to D28. Conclusion: The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population. (C) 2015 S. Karger AG, Basel
conferenceObject Foveal choroidal thickness using spectral-domain optical coherence tomography in diabetic patients during the water-drinking test(2016) PRETI, Rony; ABALEM, Maria Fernanda; GARCIA, Rafael; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro C.; ZACHARIAS, Leandro C.; PIMENTEL, Sergio Luis Gianotti; SUSANNA, Remo; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.- Confluent Endpoint Subthreshold Argon Laser for Serous Macular Detachment in Tilted Disc Syndrome Refractory to Anti-VEGF(2017) ABALEM, Maria Fernanda; CARRICONDO, Pedro Carlos; SANTOS, Helen Nazareth Veloso dos; GARCIA, Rafael; QIAN, Cynthia X.; HELAL JR., John; SOUZA, Eduardo Cunha de; TAKAHASHI, Walter YukihikoA 70-year-old woman presented with 20/200 visual acuity in the right eye. Multimodal imaging revealed tilted disc syndrome (TDS) with macular serous detachment (MSD) and pigmentary changes at the temporal margin of the optic disc. Subretinal fluid persisted after three monthly intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) injections and threshold focal laser photocoagulation. Subsequently, confluent subthreshold argon laser was applied over the entire area of retinal pigment epithelium (RPE) abnormalities, resulting in the resolution of subretinal fluid without recurrence through 3 years of followup. Subthreshold argon laser treatment may serve as a therapeutic option for MSD in TDS. Targeting leakage sites and stimulating RPE cells might help absorb subretinal fluid.
conferenceObject Association of the Y402H polymorphism of CFH gene with response of exudative AMD to intravitreal VEGF inhibitors in the Brazilian population(2014) MEDINA, Flavio Mac Cord; MOTTA, Augusto Lopes Alves da; TAKAHASHI, Walter Y.; CARRICONDO, Pedro Carlos; MOTTA, Mario Martins dos Santos; MELO, Monica B.; VASCONCELLOS, Jose Paulo C.conferenceObject Retinal blood vessels diameters in unilateral ischemic central retinal vein occlusion using infrared imaging.(2016) GARCIA, Rafael; ABALEM, Maria Fernanda; PRETI, Rony; SANTOS, Helen Nazareth Veloso; CARRICONDO, Pedro Carlos; ZACHARIAS, Leandro C.; PIMENTEL, Sergio Luis Gianotti; TAKAHASHI, Walter Y.; MONTEIRO, Mario L. R.- Socioeconomic Barriers to Rhegmatogenous Detachment Surgery in Brazil(2014) CARRICONDO, Pedro Carlos; TANAKA, Tatiana; SHIBATA, Suellen Tiemi; ZACHARIAS, Leandro Cabral; LEITE, Thiago Aragao; ABALEM, Maria Fernanda; TAKAHASHI, Walter Y.Purpose. To verify access barriers patients with retinal detachment face to arrive at a reference center and to evaluate patients' knowledge about the disease. Methods. Transversal study that applied a questioner to 65 patients of the Clinical Hospital of the University of Sao Paulo with retinal detachment between February and August of 2010. Results. Reasons for not performing the surgery in other services were as follows: 47% were referred because there was not vitreoretinal surgeon at original service; 27% could not afford the surgery, had no health insurance, or had no coverage at health insurance plan for the procedure. Time between the first symptom and the arrival at our service was as follows: 18 patients arrived in up to 7 days; 35 between 8 and 30 days; 8 between 31 and 90 days; 5 in more than 90 days. Reasons for delay were as follows: 70% did not know how serious the pathology was; 56% thought that it had spontaneous cure; 16% did not have money to pay for ophthalmic evaluation, 10% did not know where to go and 24% for other reasons. Conclusion. Educational programs about disease and measures to optimize the referral to specialized services are needed to accelerate the treatment of patients with rhegmatogenous retinal detachment.
- Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population(2019) MEDINA, Flavio Mac Cord; MOTTA, Augusto Alves Lopes da; TAKAHASHI, Walter Yukihiko; CARRICONDO, Pedro Carlos; MOTTA, Mario Martins dos Santos; MELO, Monica B.; VASCONCELLOS, Jose Paulo C.Aim: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population. Methods: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the number of injections over 1 year of follow-up were correlated with CFH genotypes. Results: The analysis of variance for the difference between the BCVA denoted as logMAR (logarithm of the minimum angle of resolution) values showed an improvement at 1 year when compared to baseline (p = 0.039). Profile contrast analysis showed that this difference was significant only in the group without the C allele (p = 0.049), without significance in patients presenting with the risk allele (p = 0.241). CRT showed a mean reduction at 1 year compared to baseline (p < 0.001). Significant differences in the profile contrast test were found in the group without the C allele (p < 0.001) and in patients with the risk allele (p = 0.002). No difference was found in the number of injections among the different groups (p = 0.787). Conclusions: The presence of the risk allele of the Y402H polymorphism in the CFH gene was related to a less favorable evolution over 1 year in this sample of the Brazilian population with exudative AMD who were being treated with anti-VEGF drugs. In agreement with similar previous studies, this study concludes that the CFH risk genotypes may affect the disease response to treatment. (C) 2017 S. Karger AG, Basel